News Content
Its core metabolic characteristics are "short half-life and rapid clearance." Mesterolone has an average half-life of only 2-3 hours, reaching peak blood concentration 1-2 hours after oral administration. It is then rapidly metabolized by the liver. In healthy men, a single 25mg oral dose results in approximately 80% of the drug being excreted in the urine as metabolites within 24 hours, and the parent drug is virtually undetectable in the blood after 48 hours. This short metabolic cycle means that to maintain stable efficacy, the drug must be taken in two to three divided doses daily to avoid significant fluctuations in blood concentrations.https://www.fiercerawsource.com/steroid-finished/steroid-finished-tablets/stromusc-pills-25mg-proviron-mesterolone-100.html
However, the "detection window" is even more critical than simply its retention time. Although the parent drug is rapidly cleared, its metabolites (such as 1α-methyl-5α-androstane-3α,17β-diol) remain in the body longer. Conventional urine tests can detect mesterolone within 7-10 days after discontinuation. Using the more sensitive liquid chromatography-mass spectrometry (LC-MS/MS) technique, the detection window can be extended to approximately 14 days. This is particularly important for athletes subject to doping control, as mesterolone is listed as a banned substance by the World Anti-Doping Agency (WADA). Sufficient metabolism time must be allowed after discontinuation to minimize the risk of violations.
Individual metabolic differences can also extend this "time variable." In individuals with impaired liver function, due to reduced drug metabolism, the retention time of the parent drug and its metabolites may be prolonged by 30%-50%, necessitating appropriate adjustments to dosing intervals. Long-term use of liver enzyme inducers (such as certain anti-epileptic drugs) accelerates mesterolone metabolism, shortening its retention time in the body and potentially requiring increased dosage to maintain efficacy.
Pharmaceutical experts point out that "understanding Proviron's in vivo retention time is essentially about balancing efficacy and safety. Regular dosing is necessary to cover the therapeutic window, while also minimizing detection risks and cumulative side effects based on metabolic characteristics. In particular, it is important to avoid blindly increasing the dosage due to the perception of 'short-term clearance.'"
